Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/24068Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Sharma, Anil K | - |
| dc.contributor.author | Khuller, G K | - |
| dc.date.accessioned | 2013-11-22T08:54:52Z | - |
| dc.date.available | 2013-11-22T08:54:52Z | - |
| dc.date.issued | 2001-12 | - |
| dc.identifier.issn | 0975-1009 (Online); 0019-5189 (Print) | - |
| dc.identifier.uri | http://hdl.handle.net/123456789/24068 | - |
| dc.description | 1214-1219 | en_US |
| dc.description.abstract | A large number of subunit vaccine candidates have recently been developed as alternatives to Mycobacterium bovis Bacillus Calmette-Guerin (BCG), which gives unpredictable and highly variable protection against tuberculosis. Immunological potential of various recombinant proteins against mycobacterial infections has been discussed. Further, strategies have been suggested, which include development of constructs coexpressing cytokines or regimens utilizing recombinant proteins for further improving the protective efficacy. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | NISCAIR-CSIR, India | en_US |
| dc.rights |  CC Attribution-Noncommercial-No Derivative Works 2.5 India | en_US |
| dc.source | IJEB Vol.39(12) [December 2001] | en_US |
| dc.title | Recombinant mycobacterial proteins Future directions to improve protective efficacy | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | IJEB Vol.39(12) [December 2001] | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJEB 39(12) 1214-1219.pdf | 1.59 MB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.